Lansoprazole

Lansoprazole
Clinical data
Pronunciation /lænˈsprəzl/ lan-SOH-prə-zohl
Trade names Prevacid, others
AHFS/Drugs.com Monograph
MedlinePlus a695020
License data
Pregnancy
category
  • AU: B3
  • US: B (No risk in non-human studies)
Routes of
administration
Oral, IV
ATC code A02BC03 (WHO)
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: OTC
Pharmacokinetic data
Bioavailability 80% or more
Protein binding 97%
Metabolism Hepatic (CYP3A4- and CYP2C19-mediated)
Biological half-life 1–1.5 hours
Excretion Renal and fecal
Identifiers
CAS Number 103577-45-3 YesY
PubChem (CID) 3883
IUPHAR/BPS 7208
DrugBank DB00448 YesY
ChemSpider 3746 YesY
UNII 0K5C5T2QPG YesY
KEGG D00355 YesY
ChEBI CHEBI:6375 YesY
ChEMBL CHEMBL480 YesY
ECHA InfoCard 100.173.220
Chemical and physical data
Formula C16H14F3N3O2S
Molar mass 369.363 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture
  (verify)

Lansoprazole, sold under the brand name Prevacid among others, is a medication which inhibits the stomach's production of acid. There is not evidence that its effectiveness is different than that of other PPIs.[1] Lansoprazole, given through a nasogatric tube, effectively controls pH inside the stomach and is an alternative to intravenous pantoprazole in people who are unable to swallow solid-dose formulations.[2]

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.[3] It is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and levolansoprazole.[4] Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift. Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression).[5] The effects of the medication last for over 24 hours after it has been used for a day or more.[6]

It is manufactured by a number of companies worldwide under several brand names. In the United States, it was first approved by the Food and Drug Administration (FDA) in 1995.[7] Prevacid patent protection expired on November 10, 2009.[8][9]

Medical uses

Lansoprazole is used for treatment of:

There is no good evidence that it works better than other PPIs.[1]

Side effects

Side effects of PPIs in general[10] and lansoprazole in particular[11] may include:

PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea.[6]:22

Interactions

Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI.[15]

Lansoprazole possibly interacts with, amongst other drugs:

Availability

Prevacid 30 mg

The lansoprazole molecule is off-patent and so generic drugs are available under many brand names in many countries;[17] there are patents covering some formulations in effect as of 2015.[18]

Since 2009, lansoprazole has been available over the counter (OTC) in the U.S. in a marketed by Novartis as Prevacid 24HR.[19][6][20] In Australia, it is marketed by Pfizer as Zoton.

Research

In vitro experiments have shown that lansoprazole binds to the pathogenic form of tau protein.[21] As of 2015 laboratory studies were underway on analogs of lansoprazole to explore their use as potential PET imaging agents for diagnosing tauopathies including Alzheimer's disease.[21] Lansoprazole is also a prodrug that targets the cytochrome bc1 complex of Mycobacterium tuberculosis once converted to lansoprazole sulfide in mycobacterial host cells.[22]

References

  1. 1 2 "[99] Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Retrieved 14 July 2016.
  2. Freston, James; Chiu, Yi-Lin; Pan, Wei-Jian; Lukasik, Nancy; Taubel, Jorg (2001). "Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously". The American Journal of Gastroenterology. 96 (7): 2058–2065. doi:10.1111/j.1572-0241.2001.03939.x. ISSN 0002-9270. PMID 11467632.
  3. http://www.patient.co.uk/showdoc/30002943/
  4. "Pharmacy Benefit Update". Retrieved 2 July 2014.
  5. "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. Retrieved April 14, 2007.
  6. 1 2 3 4 "Prevacid 24HR Label" (PDF). May 2010. Retrieved November 15, 2014.
  7. Mosby's Drug Consult: Lansoprazole
  8. Prevacid drug patents
  9. Teva to release Prevacid version when patent expires
  10. British National Formulary (Free registration required) 1.3.5 Proton pump inhibitors
  11. British National Formulary (Free registration required) Lansoprazole
  12. "Prevacid (Lansoprazole) Drug Information: Side Effects and Drug Interactions - Prescribing Information at RxList". RxList. Retrieved 2016-02-09.
  13. K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225
  14. Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL. Dermatology. St. Louis: Mosby. p. 154. ISBN 1-4160-2999-0..
  15. British National Formulary (Free registration required) Lansoprazole interactions
  16. Piscitelli, S. C.; Goss, T. F.; Wilton, J. H.; d'Andrea, D. T.; Goldstein, H; Schentag, J. J. (1991). "Effects of ranitidine and sucralfate on ketoconazole bioavailability". Antimicrobial Agents and Chemotherapy. 35 (9): 1765–1771. PMC 245265Freely accessible. PMID 1952845.
  17. drugs.com International availability of lansoprazole Page accessed February 3, 2015
  18. drugs.com Generic lansoprazole Page accessed February 3, 2015
  19. "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (PDF) (Press release). November 12, 2009. Retrieved November 13, 2009.
  20. "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (Press release). November 12, 2009. Retrieved November 13, 2009.
  21. 1 2 Villemagne, VL; Fodero-Tavoletti, MT; Masters, CL; Rowe, CC (January 2015). "Tau imaging: early progress and future directions.". The Lancet. Neurology. 14 (1): 114–24. doi:10.1016/s1474-4422(14)70252-2. PMID 25496902.
  22. Rybniker, Jan; et al. (July 2015). "Lansoprazole is an antituberculous prodrug targeting cytochrome bc1". Nature Communications. 6: 7659. doi:10.1038/ncomms8659. PMC 4510652Freely accessible. PMID 26158909.
This article is issued from Wikipedia - version of the 11/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.